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ABSTRACT
Extended interval dosing of the echinocandins has been suggested as a potential strategy to overcome
the need for daily intravenous administration. This study evaluated the therapeutic and prophylactic
efficacy of single doses of aminocandin, a new echinocandin in preclinical development, in a murine
model of invasive candidiasis. For therapy, groups of mice were infected with Candida albicans, followed
by a single dose of aminocandin (1–15 mg ⁄ kg) or placebo (mannitol 5% w ⁄v) administered 1 day after
inoculation. As prophylaxis, mice were given a single dose (5 or 30 mg ⁄kg) of aminocandin,
caspofungin, or placebo at increasing intervals between dose and inoculation. In both treatment and
prophylaxis studies, survival was assessed at 21 days post-inoculation. The reduction in fungal burden
was assessed in kidney tissue on day 8 post-inoculation. For treatment, single doses of aminocandin of
‡2.5 mg ⁄ kg prolonged survival significantly. In addition, the two doses evaluated for reductions in
fungal burden (5 and 15 mg ⁄ kg) revealed fungicidal activity. As prophylaxis, both aminocandin and
caspofungin 5 and 30 mg ⁄ kg prolonged survival when given 7 days before inoculation. Aminocandin
and caspofungin 30 mg ⁄ kg were both able to prolong survival when the interval between dose and
inoculation was increased to 10 days. When this interval was extended to 14 days, only aminocandin
30 mg ⁄kg prolonged survival and reduced fungal burden. These results demonstrate that single doses
of aminocandin are effective as treatment and prophylaxis, and suggest that extended interval dosing
may be a useful strategy for treating invasive candidiasis.
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INTRODUCTION
The echinocandin class of antifungal agents has
been shown in both in-vivo and clinical studies to
be effective in the treatment of invasive fungal
infections. By inhibiting a fungal specific target,
b-(1,3)-glucan synthase,membersof this classavoid
the drug interactions and toxicities associated with
the azoles and amphotericin B [1]. Clinical studies
have shown that the currently available echino-
candins (anidulafungin, caspofungin and mica-
fungin) are effective in the treatment of invasive
infections causedbyCandida spp. [2–4]. In addition,
dose-escalation studies have demonstrated that
members of this class are relatively well-tolerated
at doses above those currently used clinically [5,6].
Aminocandin (IP960) is a new echinocandin
currently undergoing preclinical development and
phase I trials. Like other echinocandins, amino-
candin has demonstrated in-vivo activity against
various Candida spp., including fluconazole-resis-
tant Candida albicans and Candida tropicalis [7–11].
Because of the long half-lives achieved clinically
and the tolerability observed in dose-escalation
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trials, extended interval dosing of the echinocan-
dins has been suggested as a means of overcoming
the need for daily intravenous therapy. This strat-
egy may allow antifungal drugs to be given at less
frequent intervals for prophylaxis or treatment of
invasive fungal infections; indeed, such an appro-
ach has been shown to be effective as treatment in
murine models of invasive candidiasis [8,9].
The aim of the present study was to assess the
utility of single doses of aminocandin as both
treatment and prophylaxis against invasive candi-
diasis. An established murine model of dissemi-
nated candidiasis was used in which animals were
infectedwithC. albicans and followeduntil 21 days
post-inoculation. The primary endpoint was sur-
vival following single doses of aminocandin.
Reductions in fungal burden within kidney tissue
were also assessed as a secondary measure of
efficacy.
MATERIALS AND METHODS
Antifungal agents
Stock solutions were prepared by dissolving aminocandin
(Indevus Pharmaceuticals, Lexington, MA, USA) in mannitol
5% w ⁄v, and by dissolving caspofungin (Merck, Whitehouse
Station, NJ, USA) in water.
Test isolate
C. albicans clinical isolate 2823 was obtained from the Fungus
Testing Laboratory at The University of Texas Health Science
Center at San Antonio (San Antonio, TX, USA). Microdilution
broth susceptibility tests were performed according to CLSI
recommendations [12] before in-vivo experiments. The MICs of
both aminocandin and caspofunginwere 0.06 mg ⁄L. For animal
studies, isolate 2823was grownovernight at 37C in brain–heart
infusion broth. Yeast cells were collected, washed in sterile
saline, and verified with a haemocytometer. Inocula sizes were
determined by plating serial dilutions and counting colonies.
Animal model
Immunocompetent outbred male ICR mice (Harlan Sprague
Dawley) weighing c. 24 g were used in all experiments. Mice
were housed five mice to a cage and had access to food and
water ad libitum. On day 0, each mouse was infected intrave-
nously with 0.2 mL of saline containing 106 CFU of C. albicans.
All animal research procedures were approved by the
Institutional Animal Care and Use Committee of The
University of Texas Health Science Center at San Antonio.
Prophylaxis and treatment studies
For treatment, animals received aminocandin at doses of 1, 2.5,
5, 10, 12.5 or 15 mg ⁄ kg as a single intravenous dose 1 day after
inoculation. In prophylaxis studies, aminocandin or
caspofungin were administered as a single 5 or 30 mg ⁄ kg
intravenous or intraperitoneal dose, respectively, at 7, 10 or
14 days before inoculation. Control animals received mannitol
5% w ⁄v (placebo) by intravenous administration. To assess
survival, mice were followed until day 21 post-inoculation.
Any animal that appeared moribund (ruffled hair, hunched
posture, cool to touch, >10% weight loss, or immobile) was
killed humanely and death was recorded as occurring the next
day. For tissue burden, separate groups of mice were followed
until day 8 post-inoculation. The animals were then killed
humanely and the kidneys were harvested and weighed. The
kidneys of animals that died before day 8 were harvested on
the day of death. Kidneys were then homogenised using
a PT2100 tissue homogeniser (Kinematica, Cincinnati, OH,
USA) in sterile saline supplemented with piperacillin and
amikacin 60 mg ⁄L. Serial dilutions were prepared and plated
in duplicate on Sabouraud dextrose agar. After incubation for
24 h at 37C, the number of CFU ⁄ g of tissue was calculated.
Each experiment contained nine or ten animals ⁄dose group.
Statistical analysis
Survival was assessed by Kaplan–Meier analysis, and differ-
ences in median survival time and survival among groups
were analysed by the log-rank and chi-square test, respec-
tively. The Mann–Whitney U-test was used for comparison of
the tissue burden among groups. A p value of £0.05 was
considered to be statistically significant. All analyses were
performed using Prism v.4.0 (GraphPad Software, Inc., San
Diego, CA, USA).
RESULTS
Treatment
Aminocandin was effective at improving survival
and reducing fungal burden following a single
intravenous dose administered 1 day after inocu-
lation with C. albicans.As shown in Table 1, single
doses of ‡2.5 mg ⁄ kg were effective in prolonging
the median survival to >21 days, which was
Table 1. Survival and tissue fungal burden following a
single dose of aminocandin administered as therapy 1 day
after intravenous inoculation of mice with Candida albicans
Treatment group
Percentage survival
(p value vs. placebo)
Median survival
(p value vs. placebo)
Placebo 15 11
AMN 1 mg ⁄ kg 0 (p 0.22) 15 (p 0.37)
AMN 2.5 mg ⁄ kg 55.6 (p <0.01) >21 (p <0.01)
AMN 5 mg ⁄ kg 77.8 (p <0.01) >21 (p <0.01)
AMN 7.5 mg ⁄ kg 66.7 (p <0.01) >21 (p 0.02)
AMN 10 mg ⁄ kg 100 (p <0.01) >21 (p <0.01)
AMN 12.5 mg ⁄ kg 90 (p <0.01) >21 (p <0.01)
AMN 15 mg ⁄ kg 90 (p <0.01) >21 (p <0.01)
Fungal burden Median log10 CFU ⁄ g (range) p value vs. placebo
Placebo 6.6 (5.8–7.0) –
AMN 5 mg ⁄ kg 2.1 (1.3–2.6) p <0.01
AMN 15 mg ⁄ kg 2.0 (1.1–3.5) p <0.01
AMN, aminocandin.
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significantly longer than the survival of controls
(11 days; p £0.02). In addition, the same doses of
aminocandin increased the percentage of animals
surviving to the predetermined study endpoint of
21 days post-inoculation to ‡55%. These values
were significantly greater than the survival rates
for animals given placebo (15%; p <0.01) or
aminocandin 1 mg ⁄ kg (0%; p 0.22 vs. placebo).
Aminocandin also resulted in significant reduc-
tions in fungal burden when administered as
single-dose therapy (Table 1). Both of the doses
evaluated (5 and 15 mg ⁄kg) reduced fungal bur-
den within the kidney tissue by >4 log10 CFU ⁄g
of tissue (to 2.1 and 2.0 log10 CFU ⁄ g, respectively)
compared to controls (6.6 log10 CFU ⁄ g; p <0.01)
by day 8 post-inoculation.
Prophylaxis
Based on the prolonged survival and reduced
tissue burden observed in the treatment studies
with aminocandin, single-dose prophylaxis stud-
ies were initiated, using increasing intervals
between dose administration and inoculation.
As a positive comparator, caspofungin prophy-
laxis was administered at the same doses and
intervals between administration and inoculation.
Both doses of aminocandin and caspofungin
tested (5 and 30 mg ⁄kg) were effective at pro-
longing survival compared to controls receiving
placebo when administered 7 days before inocu-
lation (Fig. 1a). While caspofungin 5 mg ⁄ kg
increased median survival (15.5 days) compared
to controls (2 days; p <0.01), only 30% of animals
survived to day 21 post-inoculation. This differ-
ence was not significant compared to controls
(0%; p 0.06). Furthermore, this dose of caspofun-
gin did not result in a decrease in fungal burden
(5.8 vs. 6.2 log10 CFU ⁄ g for controls; p 0.63)
(Fig. 1d). This may reflect the higher inoculum
achieved in this experiment compared to the
other prophylaxis studies (Fig. 1). However,
this higher inoculum did not affect the potency
of either aminocandin 5 and 30 mg ⁄ kg or the
high dose of caspofungin. These regimens
increased the median survival to >21 days and
the percentage of animals in each group surviv-
ing to day 21 compared to controls (90%, 100%
and 60%, respectively; p <0.01). Each of these
doses also reduced tissue fungal burden signifi-
cantly compared to controls (4.3, 1.3 and
5.1 log10 CFU ⁄ g, respectively).
(a) (b) (c) 
(d) (e) (f) 
Fig. 1. Survival (a, b and c) and tissue fungal burden (d, e and f) of mice given placebo ( ), aminocandin 5 mg ⁄ kg ( ),
aminocandin 30 mg ⁄ kg ( ), caspofungin 5 mg ⁄ kg ( ) or caspofungin 30 mg ⁄kg ( ) as a single dose at 7 days (a and d),
10 days (b and e) and 14 days (c and f) before inoculation with Candida albicans.
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When the interval between the single prophy-
lactic dose and inoculation was increased to
10 days, only aminocandin and caspofungin
30 mg ⁄ kg remained effective at prolonging sur-
vival (>21 days for both drugs) and improving
the survival rate (100% and 70%) compared
to controls (median survival 11 days, p £0.02;
10% survival, p £0.02) (Fig. 1b). In addition,
aminocandin 30 mg ⁄ kg reduced tissue fungal
burden by >4 log10 CFU ⁄g compared to controls
(1.9 vs. 6.1 log10 CFU ⁄ g, respectively; p <0.01)
(Fig. 1e). Despite improvements in survival,
caspofungin 30 mg ⁄kg did not reduce the fungal
burden significantly (5.8 log10 CFU ⁄ g; p 0.28 vs.
controls).
As the interval between the single prophylactic
dose and inoculation was further extended to
14 days, only aminocandin 30 mg ⁄ kg remained
effective at prolonging survival (median
>21 days) and the percentage of animals surviv-
ing to the predetermined endpoint (80%) com-
pared to controls (median survival 10 days,
p <0.01; 10% survival, p <0.01) (Fig. 1c). This
dose of aminocandin also suppressed the fungal
burden effectively following a single dose admin-
istered 2 weeks before inoculation (1.5 vs.
6.1 log10 CFU ⁄ g for controls, p <0.01) (Fig. 1f).
Although aminocandin 5 mg ⁄kg showed a trend
toward improved survival (median survival
18 days, p 0.093; 50% survival, p 0.051), these
values did not reach statistical significance.
In contrast, caspofungin 30 mg ⁄ kg was not effec-
tive at improving survival (median survival
12 days, p 0.40) or reducing fungal burden
(6.1 log10 CFU ⁄g, p 0.84) when administered as
a single dose 14 days before inoculation.
DISCUSSION
Members of the echinocandin class of antifungal
agents have improved tolerability and similar
efficacy, compared to azole antifungals and
amphotericin B, for the treatment of invasive
candidiasis. In randomised controlled trials, each
of the echinocandins currently available for clin-
ical use (anidulafungin, caspofungin and mica-
fungin) has been shown to yield a favourable
response in c. 70% of patients [2–4]. In addition,
trials that have compared caspofungin and
micafungin to amphotericin B deoxycholate and
liposomal amphotericin B, respectively, have
revealed that the echinocandins were better
tolerated, with fewer infusion-related reactions
and less nephrotoxicity [2,3].
While no clinical efficacy data are currently
available for aminocandin, several in-vivo studies
have evaluated this echinocandin for the treatment
of infections caused by Candida spp. Using an
immunocompromised murine model of invasive
candidiasis caused by afluconazole-resistant strain
of C. tropicalis, Warn et al. [7] demonstrated that
daily doses of aminocandin of ‡1 mg ⁄ kg were
as effective as amphotericin B deoxycholate
5 mg ⁄ kg ⁄day in prolonging survival and reducing
tissue fungal burden. In amurinemodel of invasive
candidiasis caused by C. albicans, Andes et al. [13]
demonstrated that aminocandin has concentra-
tion-dependent pharmacodynamic activity in vivo,
with large infrequent drug administration being
most effective at reducing the fungal burden [14].
Similarly, other in-vivo studies have revealed
concentration-dependent activity for anidulafun-
gin, caspofungin and micafungin, thus raising the
possibility of extended interval dosing for the
echinocandins [9–11].
Large single doses of micafungin and amino-
candin have been shown to be effective as therapy
against invasive candidiasis. Gumbo et al. [9]
demonstrated that a single dose of micafungin
100 mg ⁄kg resulted in fungicidal activity in mice
infected with Candida glabrata. Similarly, amino-
candin doses of 5 and 10 mg ⁄ kg, administered
either once- or twice-weekly, reduced fungal
burden significantly and resulted in 100% sur-
vival when begun 2 h after inoculation with a
fluconazole-resistant strain of C. albicans [8]. The
results of the current study are consistent with
these data and support the strategy of extended
interval dosing. In the present study, single
intravenous doses of aminocandin ‡2.5 mg ⁄ kg,
begun 24 h after inoculation with C. albicans,
prolonged survival significantly compared with
controls. In addition, both of the single doses
evaluated (5 and 15 mg ⁄ kg) resulted in a
significant reduction in the fungal burden
(>3 log10 CFU ⁄ g reduction).
The excellent safety and drug interaction pro-
file of the echinocandins, as well as the significant
morbidity and financial burden associated with
invasive candidiasis, mean that there is consider-
able interest in the use of members of this class as
prophylaxis against invasive fungal infections in
high-risk patients [14,15]. In a prospective double-
blind randomised trial involving autologous and
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allogeneic stem-cell transplant recipients in the
pre-engraftment period, micafungin was shown
to be of similar effectiveness to fluconazole in
preventing breakthrough candidiasis [16]. One of
the limitations of echinocandin prophylaxis is the
requirement for daily intravenous administration
for the period during which patients are at risk for
fungal infections. In the animal model used in the
present study, single doses of aminocandin and
caspofungin at 5 and 30 mg ⁄kg were effective
at prolonging survival and reducing fungal bur-
den when administered as a single prophylactic
dose 7 days before inoculation. Aminocandin
30 mg ⁄kg maintained efficacy when the interval
between prophylaxis and inoculation was
extended to 10 and 14 days, while caspofungin
30 mg ⁄kg remained protective at an interval of
10 days. Thus, extended interval dosing could
potentially overcome the limitation of daily
administration of an echinocandin. However,
further study is required to clarify this point, as
daily administration of aminocandin or caspofun-
gin was not evaluated.
One potential limitation of the present study
was the difference in the route of administration
between aminocandin (intravenous) and caspo-
fungin (intraperitoneal). Previous animal studies
have demonstrated rapid absorption of caspofun-
gin from the peritoneal space into the blood-
stream following intraperitoneal administration
[11,17]. Thus, differences in the time required to
attain peak concentrations for these two agents
that occur between the two routes of administra-
tion may be negligible, and would probably have
no effect on the results of the current study, since
the minimal interval between the prophylactic
dose and inoculation was 7 days. In addition,
the pharmacokinetics of the two agents in the
mouse model were not assessed as a potential
explanation for the effectiveness of single-dose
prophylaxis at extended intervals between
administration and inoculation. Other investiga-
tors have reported long half-lives in mice (20.2–
23.2 h) for both agents when serum concentration
data alone are assessed [11,13]. When caspofun-
gin serum concentration data were co-modelled
with kidney tissue concentrations, the terminal
half-life increased significantly to 59.2 h [11].
However, this strategy needs to be evaluated in
an immunocompromised model of invasive
candidiasis, as the immune status may affect
treatment outcome [18].
While aminocandin has been shown to be well-
tolerated in single-dose-escalation studies in
healthy volunteers, no efficacy data currently
exist. The results of the present study, as well as
those from other investigators, demonstrate that
single doses of aminocandin, caspofungin and
micafungin are effective, either as treatment or
prophylaxis, in murine models of invasive candi-
diasis. These data suggest that extended interval
dosing may be a useful strategy for combating
and preventing infections caused by Candida spp.
However, it remains to be determined whether
the maximum tolerated doses will be suffi-
ciently high to allow clinical trials of once-weekly
administration of echinocandins for treatment or
prophylaxis of invasive candidiasis. Further
investigations are warranted to determine the
clinical feasibility of this approach.
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